integratedbiotherapeutics产品代理

Integrated   BioTherapeutics, Inc. (IBT) is a biotechnology company focused on the   discovery of novel vaccines and therapeutics for emerging infectious   diseases. IBT’s pipeline includes promising product candidates for bacterial and   viral infections. IBT’s bacterial program is focused on countermeasures against   staphylococcal infections, primarily by targeting a variety of toxins   produced by S. aureus. IBT’s S. aureus vaccine, now spun off into Integrated BioTherapeutic   Vaccines, is entering the clinic in 2022.    IBT’s antiviral pipeline includes unique Ebola and Marburg antibody therapeutics,   vaccines for filoviruses and Nipah virus, and a strong discovery pipeline for   emerging viruses. Further, IBT developed a novel antibody engineering   technology for targeting anti-toxin antibodies to the surface of bacteria,   integrating toxin neutralization with effector functions.

In addition   to the active anti-infectious disease discovery pipeline at IBT, we also   operate a CRO business called IBT Bioservices which provides state of the art   infectious disease discovery capabilities critical reagents as well as animal   model testing services to industrial and academic clients.

Located in Rockville, Maryland, IBT has a close working relationship with United States Government agencies including the National Institute of Allergy and Infectious Diseases (NIAID/NIH), National Cancer Institute (NCI), Department of Defense (DOD), United States Army Medical Research Institute of Infectious Diseases (USAMRIID), and many biotechnology and pharmaceutical companies and academic laboratories.